Believe in RNAi
The gates for gene and cell therapies are open – and RNAi technology could be a serious contender for the therapy of the future.
Geert Cauwenbergh |
The discovery of RNA interference (RNAi) was regarded by the scientific community as a crucial advance – evidenced by the selection of RNAi as Science journal’s 2002 “Breakthrough of the Year” and the fact that its co-discoverers, Andrew Fire and Craig Mello, were awarded the 2006 Nobel Prize in Medicine. RNAi has high specificity for targeted genes and high potency – and because of its ability to silence genes, RNAi is being investigated as a platform for the development of novel therapies by many researchers, including those in our company (co-founded by Mello).
Read the full article now
Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE and always will be!